Estonia
Icosagen, founded in 1999, is a distinguished European CRDMO (Contract Research, Development, and Manufacturing Organization) with a remarkable track record of more than 26 years as an independent family-owned enterprise. The company has earned its reputation by integrating pre-clinical CRO (Contract Research Organization) and clinical CDMO (Contract Development and Manufacturing Organization) services at a single location. This strategic consolidation allows Icosagen to proficiently handle the journey of therapeutic antibodies, multispecifics, ADCs, and other complex recombinant protein drug candidates from discovery to clinical production.
With its state-of-the-art facilities, including a 200/1000L GMP (Good Manufacturing Practice) facility, Icosagen excels in seamlessly transitioning research concepts into viable pre-clinical and clinical solutions. Their capacity to scale from small-scale transient productions to robust cell line development underscores their versatility and commitment to quality. However, specific details about their headquarters or recent investments haven't been disclosed, which may warrant further inquiry.
